This is the authors' abstract. We don't add key points for this paper.
These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Blackwell et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: